BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 22, 2015
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg6/19 cls
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)NeedhamSerge BelangerUpgradeBuy (from hold)54%$20.02
Belanger also set a $27 target after FDA agreed to change the primary endpoint range in the Phase III Rocket 2 trial of Rhopressa to treat intraocular pressure (IOP) in glaucoma and ocular hypertension patients. The amendment will change the primary endpoint of non-inferiority to the adrenergic receptor beta (ADRB) blocker timolol to include only patients whose baseline IOP is 20-25 mmHg. The previous primary endpoint included patients...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >